Interference of Daratumumab Treatment in the Biological Monitoring of Multiple Myeloma.
Multiple myeloma is a plasma cell malignancy characterized by monoclonal immunoglobulin production. Daratumumab has improved therapeutic outcomes but can interfere with laboratory assessments.
A 73-year-old woman with IgG kappa multiple myeloma achieved remission after initial treatment, then relapsed and received DRD. A monoclonal IgG kappa spike was observed on follow-up SPEP and IFE.
Daratumumab, due to its IgG1 kappa structure, may mimic disease-related monoclonal proteins, potentially leading to false detection of residual disease and misclassification of complete response as very good partial response.
Recognizing such interference and ensuring strong clinician-biologist collaboration is essential for accurate response interpretation.
A 73-year-old woman with IgG kappa multiple myeloma achieved remission after initial treatment, then relapsed and received DRD. A monoclonal IgG kappa spike was observed on follow-up SPEP and IFE.
Daratumumab, due to its IgG1 kappa structure, may mimic disease-related monoclonal proteins, potentially leading to false detection of residual disease and misclassification of complete response as very good partial response.
Recognizing such interference and ensuring strong clinician-biologist collaboration is essential for accurate response interpretation.
Authors
Skalante Skalante, Eddair Eddair, Elidrissi Elidrissi, Echiguer Echiguer, Bella-Tedga Bella-Tedga, Biaz Biaz, Bouhsain Bouhsain, Elmaaroufi Elmaaroufi, Dami Dami, El-Machtani-Idrissi El-Machtani-Idrissi
View on Pubmed